| Literature DB >> 35865482 |
Hugues Duffau1,2.
Abstract
Early maximal surgical resection is the first treatment in diffuse low-grade glioma (DLGG), because the reduction of tumor volume delays malignant transformation and extends survival. Awake surgery with intraoperative mapping and behavioral monitoring enables to preserve quality of life (QoL). However, because of the infiltrative nature of DLGG, relapse is unavoidable, even after (supra)total resection. Therefore, besides chemotherapy and radiotherapy, the question of reoperation(s) is increasingly raised, especially because patients with DLGG usually enjoy a normal life with long-lasting projects. Here, the purpose is to review the literature in the emerging field of iterative surgeries in DLGG. First, long-term follow-up results showed that patients with DLGG who underwent multiple surgeries had an increased survival (above 17 years) with preservation of QoL. Second, the criteria guiding the decision to reoperate and defining the optimal timing are discussed, mainly based on the dynamic intercommunication between the glioma relapse (including its kinetics and pattern of regrowth) and the reactional cerebral reorganization-i.e., mechanisms underpinning reconfiguration within and across neural networks to enable functional compensation. Third, how to adapt medico-surgical strategy to this individual spatiotemporal brain tumor interplay is detailed, by considering the perpetual changes in connectome. These data support early reoperation in recurrent DLGG, before the onset of symptoms and before malignant transformation. Repeat awake resection(s) should be integrated in a global management including (neo)adjuvant medical treatments, to enhance long-lasting functional and oncological outcomes. The prediction of potential and limitation of neuroplasticity at each step of the disease must be improved to anticipate personalized multistage therapeutic attitudes.Entities:
Keywords: awake brain surgery; brain connectome; electrostimulation mapping; low-grade glioma; multistage management; neuroplasticity; quality of life; reoperation
Year: 2022 PMID: 35865482 PMCID: PMC9294369 DOI: 10.3389/fonc.2022.947933
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Original series that reported outcomes following reoperation in patients with DLGG.
| First Author (Year) | Number of Patients | Oncological Outcomes | Functional Outcomes |
|---|---|---|---|
| Schmidt et al. (2003) ( | 40 | Median time to S2: 22.5–49 months (mean: 3 years) | Not detailed |
| Martino et al. (2009) ( | 19 | Median time to S2: 4.1 years | Three improvements/three slight deficits |
| Ahmadi et al. (2009) ( | 96 | Reoperation correlated to longer OS | Not detailed |
| Kaspera et al. (2013) ( | 16 | EOR similar R1 and R2 : | Similar morbidity S1–S2 |
| Ramakrishna et al. (2015) ( | 52 | 46% of MT | 8% of permanent deficits |
| Ius et al. (2015) ( | 23 | Median time to S2: 81 months (6.75 years) | 4.35% of permanent deficits |
| Southwell et al. (2016) ( | 17 | Mean time to S2: 4.1 years | No permanent deficits |
| Spitael et al. (2017) ( | 25 | 24% of MT | Not detailed |
| Picart et al. (2019) ( | 42 | Mean time to S2: 4.1–5 years | No permanent deficits |
| Zattra et al. (2019) ( | 51 | Not detailed | Similar morbidity S1-S2 |
| Morshed et al. (2019) ( | 23 | 44.9% of MT (insular gliomas) | 8.5% of permanent deficits |
| Shofty et al. (2020) ( | 93 | Median time to S2: 38 months (3.2 years) | 5% of permanent deficits |
| Capo et al. (2020) ( | 40 | Median time to S2: 49.2 months (4.1 years) | No permanent deficits |
| Hamdan et al. (2021) ( | 31 | Median time to S2: 4 years | 3.2% of permanent deficits |
| Ng et al. (2022) ( | 62 | Median time to S2: 5.5 years | No permanent deficits |
DLGG, diffuse low-grade glioma; EOR, extent of resection; GTR, gross total resection; MT, malignant transformation; OS, overall survival; RTW, return to work; S1, first surgery; S2, second surgery; S3, third surgery.
Figure 1Factors guiding decision for reoperation in recurrent diffuse low-grade glioma (DLGG).